<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00548600</url>
  </required_header>
  <id_info>
    <org_study_id>OCOG-1992-Iridium</org_study_id>
    <nct_id>NCT00548600</nct_id>
  </id_info>
  <brief_title>Radical Radiotherapy by External Beam Radiation Versus Radical Radiotherapy With Temporary Iridium Implant Plus External Beam Radiation in Carcinoma of the Prostate</brief_title>
  <official_title>A Randomized Clinical Trial Comparing Radical Radiotherapy by External Beam Radiation Versus Radical Radiotherapy Using a Combination of a Temporaory Iridium Implant Plus External Beam Radiation in Surgically Staged B2 and C Carcinoma of the Prostate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ontario Clinical Oncology Group (OCOG)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ontario Clinical Oncology Group (OCOG)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The specific objective of this study is to compare the relative efficacy of the combination
      of a temporary iridium implant plus external beam irradiation versus standard external beam
      irradiation alone in patients with Stage B2 and C prostatic carcinoma. Benefit will be
      assessed in terms of local recurrence, survival, and toxicity.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 1992</start_date>
  <completion_date type="Actual">September 2006</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of local control as determined by biopsy at 18 months</measure>
    <time_frame>18-months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Distant metastasis</measure>
    <time_frame>survival</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall mortality</measure>
    <time_frame>survival</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality due to prostate cancer</measure>
    <time_frame>survival</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local complications of radiation</measure>
    <time_frame>2-5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">112</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Iridium implant plus external beam irradiation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard external beam irradiation alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Iridium Implant</intervention_name>
    <description>Temporary iridium implant of the prostate will be done and a dose of 3000 cGy will be delivered in the next 48-72 hours. Two weeks later 20 fractions of external beam radiation at a dose of 4000 cGy will be administered over a period of 4 weeks.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Standard external beam irradiation</intervention_name>
    <description>Standard external beam irradiation at a dose of 6400 cGy in 32 fractions over 6 and a half weeks will be administered.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients must have histologically proven adenocarcinoma of the prostate

          -  The primary tumour should be staged clinically B2 or C as classified by A.J.C. Staging
             System

        Exclusion Criteria:

          -  Patients requiring transurethral prostatectomy (TURP) prior to diagnosis

          -  Presence of metastases identified by bone scan, chest x-ray or CT scan of the abdomen
             and pelvis, or staging lymphadenectomy

          -  Karnofsky performance status less than 80

          -  Inadequate laboratory results: i.e. Hb &lt; 12 gm/litre, WBC &lt; 3.5 x 10 per litre,
             platelets &lt; 100 x 10/litre, urea &gt; 13 mmol/litre, creatinine &gt; 220 mmol/litre

          -  Unfit for surgery for other medical reasons

          -  Age above 75 years

          -  Failure to provide written informed consent
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jinka Sathya, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Juravinski Cancer Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Juravinski Cancer Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Sathya JR, Davis IR, Julian JA, Guo Q, Daya D, Dayes IS, Lukka HR, Levine M. Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate. J Clin Oncol. 2005 Feb 20;23(6):1192-9.</citation>
    <PMID>15718316</PMID>
  </reference>
  <verification_date>October 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 22, 2007</study_first_submitted>
  <study_first_submitted_qc>October 22, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2007</study_first_posted>
  <last_update_submitted>October 22, 2007</last_update_submitted>
  <last_update_submitted_qc>October 22, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 24, 2007</last_update_posted>
  <keyword>Prostate Cancer</keyword>
  <keyword>Iridium</keyword>
  <keyword>Implant</keyword>
  <keyword>Radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

